Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Table 2 Prognostic factors related to Hodgkin and Reed-Sternberg cells

Factor	Function	Number of patients	Expression level (%)	Significance, univariate^a	Significance, multivariate^a	Reference(s)
HLA class II	Immune response	292	59	+ (↓FFS, OS)	+ (↓FFS)	[51]
Topoisomerase II	DNA synthesis	238	64	+ (↓FFS)	+ (↓FFS)	[52]
		146	49	+ (↓EFS)	+(↓EFS)	[49]
MAL	T-cell activation	86	19	+ (↓FFS, OS)	+(↓FFS, OS)	[54]
		81	NA	+ (↓FFS, OS)	+ (↓FFS)	[50]
CD20	B-cell activation (?)	598	22	-	-	[74]
		248	11	+ (↓TTF, OS)	+ (↓TTF, OS)	[73]
		119	20	+ (↑TTF)	+ (↑TTF)	[75]
		166	12	-	-	[68]
		59	25	+ (↑PFS)	+ (↑PFS)	[48]
p53	Apoptosis; response to genotoxic stress	194	57	+ (↓DFS, OS)	+ (↓DFS, OS)	[44]
		49	40 to 75^b	-	-	[42]
		78	67	-	-	[43]
		259	29	+ (↓EFS, DSS)	+ (↓EFS, DSS)	[45]
		140	92	-	-	[46]
		107	10	-	-	[47]
Bcl-2	Cell survival; anti-apoptosis	140	61	-	-	[46]
		107	26	+ (↓FFS, OS)	+(↓FFS, OS)	[47]
		707	61	+ (↓FFS)	+(↓FFS)	[33]
		194	47	+ (↓DFS)	+ (↓DFS)	[44]
		81	NA	-	+ (↓FFS)	[50]
		146	40	-	-	[49]
		59	33	+ (↓PFS)	+ (↓PFS)	[48]

^aThe presence (+) or absence (-) of a significant correlation (positive ↑ or negative ↓) with the study endpoints.
^bTwo different antibodies against p53 were used in this study.
Bcl-2, B-cell lymphoma 2; DSS, disease-specific survival; EFS, event-free survival; FFS, failure-free survival; HLA, human leukocyte antigen; MAL, myelin and lymphocyte protein; NA, not applicable; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure.

ISSN: 1756-994X